<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210209050304N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-07-29</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Effect of life-style on temporomandibular joint disorders</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of life-style factors on temporomandibular disorders</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57150</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Randomization is done by the simple method and with cards. Type of intervention is written on the cards which will be put in sealed opaque envelopes. Patients are included in the list of the participants in the order of the time of their first visit and the code of the questionnaire they have completed. After entering the trial, each patient chooses an envelope after folding the cards. Envelopes are prepared according to the predicted sample size and the number of patients; Therefore, each selected envelope will not be re-entered in the randomization sequence, so there would be the same number of patients in both groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Temporomandibular joint disorder.</hc_freetext>
      <i_freetext>Intervention 1: Control group: They receive the routine pharmacotherapy regimen (Naproxen 250mg q8h AND Methocarbamol 500mg q8h for 2 weeks). Intervention 2: Intervention group: In addition to pharmacotherapy (Naproxen 250mg q8h AND Methocarbamol 500mg q8h for 2 weeks), they follow the following protocol: 1-listening to desired music at least 45 minutes daily 2-Walking or exercise of choice 30 minutes daily (At least 5 days a week) 3-Managing sleeping hours to a minimum of 7 hours daily (At least 5 days a week).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Age, sex and information on patients' life-style, without exposing their personal information and identity, and improvements on their temporomandibular disorder can be published.

When:
Starts after the trial is over.

To whom:
Researchers presenting a recommendation letter from a research center or an educational institute can access the data.

Conditions:
Data can be accessed and used for further research by researchers providing a recommendation letter from a research center or an educational institute.

Where to obtain:
Data can be obtained from the first author (Dr. Reza Tabrizi) or the oral and maxillofacial surgery department of Shahid Beheshti dental school. Contact information has been presented in the previous sections.

How to obtain:
After presenting a recommendation letter from a research center or an educational institute, the requested data will be presented to the researcher as soon as possible.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Reza Tabrizi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 2, Nabavi Ave., Shariati Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1963815971</zip>
        <telephone>+98 21 2267 2126</telephone>
        <email>tabmed@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Reza Tabrizi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 2, Nabavi Ave., Shariati Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1963815971</zip>
        <telephone>+98 21 2267 2126</telephone>
        <email>tabmed@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with Temporomandibular disorder (TMD) signs and symptoms
Patients suffering from sleep disturbance
Patients suffering from psychological distress</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients suffering from systemic diseases that affects the temporomandibular joint
History of jaw fracture or trauma
History of orthognathic surgery or other joint surgeries
Patients who have an acceptable life-style</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M26.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Temporomandibular joint disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: They receive the routine pharmacotherapy regimen (Naproxen 250mg q8h AND Methocarbamol 500mg q8h for 2 weeks).</i_keyword>
      <i_keyword>Intervention group: In addition to pharmacotherapy (Naproxen 250mg q8h AND Methocarbamol 500mg q8h for 2 weeks), they follow the following protocol: 1-listening to desired music at least 45 minutes daily 2-Walking or exercise of choice 30 minutes daily (At least 5 days a week) 3-Managing sleeping hours to a minimum of 7 hours daily (At least 5 days a week)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Joint pain. Timepoint: At the beginning of the trial and on the follow up sessions; 3, 6 and 9 months after starting the intervention. Method of measurement: Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Clicking. Timepoint: At the beginning of the trial and on the follow up sessions; 3, 6 and 9 months after starting the intervention. Method of measurement: Clinical examination.</prim_outcome>
      <prim_outcome>Maximum Mouth Opening. Timepoint: At the beginning of the trial and on the follow up sessions; 3, 6 and 9 months after starting the intervention. Method of measurement: Clinical Examination.</prim_outcome>
      <prim_outcome>Crepitus. Timepoint: At the beginning of the trial and on the follow up sessions; 3, 6 and 9 months after starting the intervention. Method of measurement: Clinical Examination.</prim_outcome>
      <prim_outcome>Stress Score according to Psychological General Well-Being Index. Timepoint: At the beginning of the trial and on the follow up sessions; 3, 6 and 9 months after starting the intervention. Method of measurement: Psychological General Well-Being Index.</prim_outcome>
      <prim_outcome>Sleep quality according to The Pittsburgh Sleep Quality Index. Timepoint: At the beginning of the trial and on the follow up sessions; 3, 6 and 9 months after starting the intervention. Method of measurement: The Pittsburgh Sleep Quality Index Questinnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-11-23</approval_date>
        <contact_name>Ethics committee of Research institute for Dental Sciences - Shahid Beheshti University Of Medical S</contact_name>
        <contact_address>13th Fl, Block A, Ministry of Health, Treatment and Medical Education Headquarters, Between Zarafshan &amp; South Falamak, Sima-Ye-Iran St, Qods Town Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
